Archive: June, 2015

 

 

Rex Bionics plc – Proposed Fundraising and Notice of General Meeting

Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, today announces a proposed Placing and Subscription of 3,500,000 New Ordinary Shares at a price of 60 pence to raise £2.1 million (before expenses).

Read more about Rex Bionics plc – Proposed Fundraising and Notice of General Meeting

Nexvet Advances Manufacturing Strategy

Nexvet has signed a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to provide future clinical-scale biomanufacturing services for Nexvet’s most advanced product candidates, NV-01 and NV-02, being developed for chronic pain management indications in dogs and cats. The contract also allows for Fujifilm to become the commercial manufacturer of these product candidates.

Read more about Nexvet Advances Manufacturing Strategy

AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of P. aeruginosa bacteriophages after exposure to nebulizer systems applicable for use in future clinical trials will be presented at the European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.

Read more about AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage

Nexvet Announces Positive Top-Line Results for Proof-of-Concept Efficacy Study of NV-02 in Cats With Degenerative Joint Disease

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including osteoarthritis, in cats. 

Read more about Nexvet Announces Positive Top-Line Results for Proof-of-Concept Efficacy Study of NV-02 in Cats With Degenerative Joint Disease

AmpliPhi’s Bacteriophage Manufacturing Facility Receives cGMP Certification

 AmpliPhi BioSciences Corporation. (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its production facility in Ljubljana, Slovenia, was cleared by JAZMP, the Agency of the Republic of Slovenia for Medicinal Products and Medical Devices, to manufacture bacteriophages under current Good Manufacturing Practices (cGMP) standards.

Read more about AmpliPhi’s Bacteriophage Manufacturing Facility Receives cGMP Certification

Rex Bionics – First Patient Treated in RAPPER II Clinical Trial

Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce that the first patient has been successfully treated in its RAPPER II (“Robot-Assisted PhysiotheraPExercises with REX”) clinical trial.

Read more about Rex Bionics – First Patient Treated in RAPPER II Clinical Trial

SeaDragon Full Year Result to 31 March 2015

SeaDragon (NZX.SEA), New Zealand’s largest refiner and blender of high quality, fish oils and fractions, including Omega 3 oils, today reports financial results in line with its March forecasts and continued progress on the development of its new Omega 3 fish oil refinery.

Read more about SeaDragon Full Year Result to 31 March 2015

Rex Bionics – Audited Results period ended 31 Mar 2015

29 May 2015, Rex Bionics Plc (AIM: RXB) the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users and enables robot assisted physiotherapy exercise, today announces...

Read more about Rex Bionics – Audited Results period ended 31 Mar 2015

AmpliPhi Provides Corporate Update and Reports First Quarter 2015 Financial Results

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided a corporate update and announced financial results for the first quarter ended March 31, 2015.

Read more about AmpliPhi Provides Corporate Update and Reports First Quarter 2015 Financial Results

Nexvet Appoints Dr. Jurgen Horn as Chief Product Development Officer

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced it has appointed former Elanco and Novartis Animal Health executive Dr. Jürgen Horn as its new Chief Product Development Officer. Dr. Horn will commence his role at Nexvet in August 2015.

Read more about Nexvet Appoints Dr. Jurgen Horn as Chief Product Development Officer

1 2